BRIM-P: A phase I, open-label, multicenter, dose-escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation-positive melanoma.
Julia C ChisholmJozef SuvadaIra J DunkelMichela CasanovaWeijiang ZhangNatasha RitchieYounJeong ChoiJane ParkMeghna Das ThakurStephen SimkoNga Wan Rachel TamAndrea C FerrariPublished in: Pediatric blood & cancer (2018)
A recommended and effective dose of vemurafenib for patients aged 12-17 years with metastatic or unresectable melanoma was not identified. Extremely low enrollment in this trial highlights the importance of considering the inclusion of adolescents with adult cancers in adult trials.
Keyphrases
- open label
- end stage renal disease
- clinical trial
- phase ii
- young adults
- newly diagnosed
- chronic kidney disease
- ejection fraction
- childhood cancer
- squamous cell carcinoma
- study protocol
- small cell lung cancer
- physical activity
- prognostic factors
- healthcare
- patient reported outcomes
- phase ii study
- cross sectional
- health insurance
- liver metastases
- metastatic colorectal cancer
- rectal cancer